Monoclonal antibody significantly reduces nasal polyps and need for surgery in Phase 3 clinical trial
Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...
Nasal Polyps Treatment Market Set To Surge To $4.24 Billion By 2030 At A 5.6% CAGR
Nasal Polyps Treatment Market Research Report The global nasal polyps treatment market is expected to reach around $4,243.9 million by 2030 ...
Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025In parallel, the ...
Taiwan News16h
Nasal Polyposis Treatment Market to Reach USD 8.0 Billion by 2032, Expanding at a 6.3% CAGR
Request To Download Free Sample of This Strategic Report @- https://reportocean.com/industry-verticals/sample-request?report_id=bw8527 ...
The Manila Times5d
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Research and development expenses were $21.8 million for the quarter ended December 31, 2024, compared to $11.6 million for ...
Drug Store News5d
FDA approves Celltrion's Xolair biosimilar
Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...
Taiwan News1d
Nasal Polyposis Treatment Market Valued at USD 4.6 Billion in 2023, Expected to Grow at 6.3% CAGR Through 2032
Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw8527 ...
Lyra Therapeutics reports Q4 EPS ($1.43), consensus (13c)
Cash and cash equivalents as of December 31 were $40.6M compared with cash, cash equivalents and short-term investments of $51.6M at ...
pharmaphorum1d
FDA says no to AZ's Fasenra for nasal polyp indication
AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...